Receptor tyrosine kinases in carcinogenesis
Authors: Pei-Ying Zhang
Xiao-Ying Zhang
Journal: Oncology Letters (2016)
Discipline: CLINICAL MEDICINE
Keywords: cancer; receptor tyrosine kinase-like orphan receptors; receptor tyrosine kinases.
Affiliations: Nanjing University of Chinese Medicine, Information Institute, Nanjing, Jiangsu 221009, P.R. China., Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China.

Abstract:  Receptor tyrosine kinases (RTKs) are cell surface glycoproteins with enzymatic activity involved in the regulation of various important functions. In all-important physiological functions including differentiation, cell-cell interactions, survival, proliferation, metabolism, migration and signaling these receptors are the key players of regulation. Additionally, mutations of RTKs or their overexpression have been described in many human cancers and are being explored as a novel avenue for a new therapeutic approach. Some of the deregulated RTKs observed to be significantly affected in cancers included vascular endothelial growth factor receptor, epidermal growth factor receptor, fibroblast growth factor receptor, RTK-like orphan receptor 1 (ROR1) and the platelet-derived growth factor receptor. These deregulated RTKs offer attractive possibilities for the new anticancer therapeutic approach involving specific targeting by monoclonal antibodies as well as kinase. The present review aimed to highlight recent perspectives of RTK ROR1 in cancer. 

Retracted: Yes

PubPeer comments:
 This review paper appears to be unexpectedly similar to a 2015 PhD thesis by Salam Khan at the Karolinska Institutet in Stockholm called  Targeting chronic lymphocytic leukemia cells using anti-ROR1 monoclonal antibodies and small molecule inhibitors . That thesis can be found here: https: openarchive.ki.se xmlui bitstream handle 10616 44620 Thesis_Salam_Khan.pdf Here is a marked-up version of the text by Zhang and Zhang 2016, with highlighted text showing similarities to the Salam Khan 2015 thesis. Generated in SimTexter : ![file] ![file] , 
 September 2020 retraction notice: https: www.spandidos-publications.com 10.3892 ol.2020.12062  Following the publication of this article, an interested reader drew to our attention that the flow of the text, and the wording of numerous passages of text within the article, bore striking and unexpected similarities to the wording employed in a PhD thesis by Salam Khan at the Karolinska Institutet in Stockholm in 2015 entitled u201cTargeting Chronic Lymphocytic Leukemia cells using Anti-ROR1 Monoclonal Antibodies and Small Molecule Inhibitorsu201d. After having conducted an internal investigation, the Editor of Oncology Letters has determined beyond all reasonable doubt that the review submitted to the Journal shared an unacceptable level of identity with the PhD thesis by Salam Khan. The authors were contacted about these apparent similarities between their review and the thesis, and they agree to this retraction. The Editor of Oncology Letters deeply regrets that this article was not intercepted by our own checks for plagiarism prior to the publication of the review, and sincerely apologizes to the author of the PhD thesis and the readership for the inconvenience caused. We also thank the reader for bringing this matter to our attention. I was the reader, and I was not notified by the journal or the publisher. ,